wet age-related macular degeneration - NICE TA800
1.1 Faricimab is recommended as an option for treating wet age-related macular degeneration in adults, only if:
the eye has a best-corrected visual acuity between 6/12 and 6/96
there is no permanent structural damage to the central fovea
the lesion size is 12 disc areas or less in greatest linear dimension
there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein angiography, or recent visual acuity changes)
the company provides faricimab according to the commercial arrangement.